Advantages of nanomedicine over the conventional treatment in Acute myeloid leukemia

References

• Zivarpour P, Hallajzadeh J, Asemi Z, et al. Chitosan as possible inhibitory agents and delivery systems in leukemia. Cancer Cell Int. 2021;21(1):544. doi: 10.1186/s12935-021-02243-w.
   PubMed Web of Science ®Google Scholar
• Wan Z, Sun R, Moharil P, et al. Research advances in nanomedicine, immunotherapy, and combination therapy for leukemia. J Leukoc Biol. 2021;109(2):425–436. doi: 10.1002/jlb.5mr0620-063rr.
   PubMed Web of Science ®Google Scholar
• De Kouchkovsky I, Abdul-Hay M. Acute myeloid leukemia: a comprehensive review and 2016 update. Blood Cancer J. 2016;6(7):e441–e441. doi: 10.1038/bcj.2016.50.
   PubMedGoogle Scholar
• Arora RS, Arora B. Acute leukemia in children: a review of the current indian data. South Asian J Cancer. 2016;5(3):155–160. doi: 10.4103/2278-330x.187591.
   PubMedGoogle Scholar
• Pelcovits A, Niroula R. Acute myeloid leukemia: a review. R I Med J. 2020;103(3):38–40.
   Google Scholar
• Rafiq S, Raza MH, Younas M, et al. Molecular targets of curcumin and future therapeutic role in leukemia. JBM. 2018;6(4):33–50. doi: 10.4236/jbm.2018.64003.
   Google Scholar
• Shallis RM, Wang R, Davidoff A, et al. Epidemiology of acute myeloid leukemia: recent progress and enduring challenges. Blood Rev. 2019;36:70–87. doi: 10.1016/j.blre.2019.04.005.
   PubMed Web of Science ®Google Scholar
• Cirri D, Schirmeister T, Seo EJ, et al. Antiproliferative properties of a few auranofin-related gold(I) and silver(I) complexes in leukemia cells and their interferences with the ubiquitin proteasome system. Molecules. 2020;25(19):4454. doi: 10.3390/molecules25194454.
   PubMed Web of Science ®Google Scholar
• Daver N, Wei AH, Pollyea DA, et al. New directions for emerging therapies in acute myeloid leukemia: the next chapter. Blood Cancer J. 2020;10(10):107. doi: 10.1038/s41408-020-00376-1.
   PubMed Web of Science ®Google Scholar
• Girigoswami A, Girigoswami K. Potential applications of nanoparticles in improving the outcome of lung cancer treatment. Genes (Basel). 2023;14(7):1370. doi: 10.3390/genes14071370.
   PubMed Web of Science ®Google Scholar
• Limongi T, Susa F, Cauda V. Nanoparticles for hematologic diseases detection and treatment. J Hematol Oncol. 2019;4:1000183. doi: 10.15761/hmo.1000183.
   Google Scholar
• Gowtham P, Arumugam VA, Harini K, et al. Nanostructured proteins for delivering drugs to diseased tissues. Bioinspired, Biomim Nanobiomaterials. 2023;12(3):115–129. doi: 10.1680/jbibn.23.00004.
   Web of Science ®Google Scholar
• Gonzalez-Valdivieso J, Girotti A, Schneider J, et al. Advanced nanomedicine and cancer: challenges and opportunities in clinical translation. Int J Pharm. 2021;599:120438. doi: 10.1016/j.ijpharm.2021.120438.
   PubMedGoogle Scholar
• Sharmiladevi P, Girigoswami K, Haribabu V, et al. Nano-enabled theranostics for cancer. Mater Adv. 2021;2(9):2876–2891. doi: 10.1039/D1MA00069A.
   Google Scholar
• Gu W, Qu R, Meng F, et al. Polymeric nanomedicines targeting hematological malignancies. J Control Release. 2021;337:571–588. doi: 10.1016/j.jconrel.2021.08.001.
   PubMed Web of Science ®Google Scholar
• Mostafavi E, Zarepour A, Barabadi H, et al. Antineoplastic activity of biogenic silver and gold nanoparticles to combat leukemia: beginning a new era in cancer theragnostic. Biotechnol Rep (Amst). 2022;34:e00714. doi: 10.1016/j.btre.2022.e00714.
   PubMedGoogle Scholar
• O’Donnell MR, Abboud CN, Altman J, et al. Acute myeloid leukemia. J Natl Compr Canc Netw. 2012;10(8):984–1021. doi: 10.6004/jnccn.2012.0103.
   PubMed Web of Science ®Google Scholar
• Deschler B, Lübbert M. Acute myeloid leukemia: epidemiology and etiology. Cancer. 2006;107(9):2099–2107. doi: 10.1002/cncr.22233.
   PubMed Web of Science ®Google Scholar
• Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–2405. doi: 10.1182/blood-2016-03-643544.
   PubMed Web of Science ®Google Scholar
• Prada-Arismendy J, Arroyave JC, Röthlisberger S. Molecular biomarkers in acute myeloid leukemia. Blood Rev. 2017;31(1):63–76. doi: 10.1016/j.blre.2016.08.005.
   PubMed Web of Science ®Google Scholar
• Othus M, Sekeres MA, Nand S, et al. Relative survival following response to 7 + 3 versus azacytidine is similar in acute myeloid leukemia and high-risk myelodysplastic syndromes: an analysis of four SWOG studies. Leukemia. 2019;33(2):371–378. doi: 10.1038/s41375-018-0275-x.
   PubMed Web of Science ®Google Scholar
• Castaigne S, Pautas C, Terré C, et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet. 2012;379(9825):1508–1516. doi: 10.1016/s0140-6736(12)60485-1.
   PubMed Web of Science ®Google Scholar
• Stone RM, Mandrekar SJ, Sanford BL, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med. 2017;377(5):454–464. doi: 10.1056/NEJMoa1614359.
   PubMed Web of Science ®Google Scholar
• DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383(7):617–629. doi: 10.1056/NEJMoa2012971.
   PubMed Web of Science ®Google Scholar
• Patel JP, Gönen M, Figueroa ME, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med. 2012;366(12):1079–1089. doi: 10.1056/NEJMoa1112304.
   PubMed Web of Science ®Google Scholar
• Burnett AK, Russell NH, Hills RK, et al. Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial. J Clin Oncol. 2013;31(27):3360–3368. doi: 10.1200/jco.2012.47.4874.
   PubMed Web of Science ®Google Scholar
• Roboz GJ. Novel approaches to the treatment of acute myeloid leukemia. Hematology Am Soc Hematol Educ Program. 2011;2011:43–50. doi: 10.1182/asheducation-2011.1.43.
   PubMedGoogle Scholar
• Attar EC, De Angelo DJ, Supko JG, et al. Phase I and pharmacokinetic study of bortezomib in combination with idarubicin and cytarabine in patients with acute myelogenous leukemia. Clin Cancer Res. 2008;14(5):1446–1454. doi: 10.1158/1078-0432.ccr-07-4626.
   PubMed Web of Science ®Google Scholar
• Mrózek K, Marcucci G, Nicolet D, et al. Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia. J Clin Oncol. 2012;30(36):4515–4523. doi: 10.1200/jco.2012.43.4738.
   PubMed Web of Science ®Google Scholar
• Burnett A, Wetzler M, Löwenberg B. Therapeutic advances in acute myeloid leukemia. J Clin Oncol. 2011;29(5):487–494. doi: 10.1200/jco.2010.30.1820.
   PubMed Web of Science ®Google Scholar
• Ghazaly EA, Miraki-Moud F, Smith P, et al. Repression of sphingosine kinase (SK)-interacting protein (SKIP) in acute myeloid leukemia diminishes SK activity and its re-expression restores SK function. J Biol Chem. 2020;295(16):5496–5508. doi: 10.1074/jbc.RA119.010467.
   PubMed Web of Science ®Google Scholar
• Chan SM, Thomas D, Corces-Zimmerman MR, et al. Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia. Nat Med. 2015;21(2):178–184. doi: 10.1038/nm.3788.
   PubMed Web of Science ®Google Scholar
• Klossowski S, Miao H, Kempinska K, et al. Menin inhibitor MI-3454 induces remission in MLL1-rearranged and NPM1-mutated models of leukemia. J Clin Invest. 2020;130(2):981–997. doi: 10.1172/jci129126.
   PubMed Web of Science ®Google Scholar
• Liao Q, Wang B, Li X, et al. miRNAs in acute myeloid leukemia. Oncotarget. 2017;8(2):3666–3682. doi: 10.18632/oncotarget.
   PubMedGoogle Scholar
• Bousquet M, Harris MH, Zhou B, et al. MicroRNA miR-125b causes leukemia. Proc Natl Acad Sci U S A. 2010;107(50):21558–21563. doi: 10.1073/pnas.1016611107.
   PubMed Web of Science ®Google Scholar
• Bai J, Guo A, Hong Z, et al. Upregulation of microRNA-100 predicts poor prognosis in patients with pediatric acute myeloid leukemia. Onco Targets Ther. 2012;5:213–219. doi: 10.2147/ott.s36017.
   PubMed Web of Science ®Google Scholar
• Wang F, Wang XS, Yang GH, et al. miR-29a and miR-142-3p downregulation and diagnostic implication in human acute myeloid leukemia. Mol Biol Rep. 2012;39(3):2713–2722. doi: 10.1007/s11033-011-1026-5.
   PubMed Web of Science ®Google Scholar
• Jiang W, Min J, Sui X, et al. MicroRNA-26a-5p and microRNA-23b-3p upregulate peroxiredoxin III in acute myeloid leukemia. Leuk Lymphoma. 2015;56(2):460–471. doi: 10.3109/10428194.2014.924115.
   PubMed Web of Science ®Google Scholar
• Trissal MC, DeMoya RA, Schmidt AP, et al. MicroRNA-223 regulates granulopoiesis but is not required for HSC maintenance in mice. PLoS One. 2015;10(3):e0119304. doi: 10.1371/journal.pone.0119304.
   PubMed Web of Science ®Google Scholar
• Su R, Lin HS, Zhang XH, et al. MiR-181 family: regulators of myeloid differentiation and acute myeloid leukemia as well as potential therapeutic targets. Oncogene. 2015;34(25):3226–3239. doi: 10.1038/onc.2014.274.
   PubMed Web of Science ®Google Scholar
• Kadia TM, Ravandi F, Cortes J, et al. New drugs in acute myeloid leukemia. Ann Oncol. 2016;27(5):770–778. doi: 10.1093/annonc/mdw015.
   PubMed Web of Science ®Google Scholar
• Li C, You X, Xu X, et al. A metabolic reprogramming amino acid polymer as an immunosurveillance activator and leukemia targeting drug carrier for T-cell acute lymphoblastic leukemia. Adv Sci (Weinh). 2022;9(9):e2104134. doi: 10.1002/advs.202104134.
   PubMedGoogle Scholar
• Huang L, Huang J, Huang J, et al. Nanomedicine – a promising therapy for hematological malignancies. Biomater Sci. 2020;8(9):2376–2393. doi: 10.1039/D0BM00129E.
   PubMed Web of Science ®Google Scholar
• Houshmand M, Garello F, Circosta P, et al. Nanocarriers as magic bullets in the treatment of leukemia. Nanomaterials (Basel). 2020;10(2):276. doi: 10.3390/nano10020276.
   PubMedGoogle Scholar
• Leventakos K, Lewis RE, Kontoyiannis DP. Fungal infections in leukemia patients: how do we prevent and treat them? Clin Infect Dis. 2010;50(3):405–415. doi: 10.1086/649879.
   PubMed Web of Science ®Google Scholar
• Kulkarni S, Pandey A, Mutalik S. Heterogeneous surface-modified nanoplatforms for the targeted therapy of haematological malignancies. Drug Discov Today. 2020;25(1):160–167. doi: 10.1016/j.drudis.2019.10.001.
   PubMed Web of Science ®Google Scholar
• Newell LF, Cook RJ. Advances in acute myeloid leukemia. BMJ. 2021;375:n2026. doi: 10.1136/bmj.n2026.
   PubMedGoogle Scholar
• Hu Q, Sun W, Wang J, et al. Conjugation of haematopoietic stem cells and platelets decorated with anti-PD-1 antibodies augments anti-leukaemia efficacy. Nat Biomed Eng. 2018;2(11):831–840. doi: 10.1038/s41551-018-0310-2.
   PubMed Web of Science ®Google Scholar
• Ci T, Li H, Chen G, et al. Cryo-shocked cancer cells for targeted drug delivery and vaccination. Sci Adv. 2020;6(50):eabc3013. doi: 10.1126/sciadv.abc3013.
   PubMed Web of Science ®Google Scholar
• Cho B-S, Kim H-J, Konopleva M. Targeting the CXCL12/CXCR4 axis in acute myeloid leukemia: from bench to bedside. Korean J Intern Med. 2017;32(2):248–257. doi: 10.3904/kjim.2016.244.
   PubMed Web of Science ®Google Scholar
• Walasek A. The new perspectives of targeted therapy in acute myeloid leukemia. Adv Clin Exp Med. 2019;28(2):271–276. doi: 10.17219/acem/81610.
   PubMed Web of Science ®Google Scholar
• Walter RB. Where do we stand with radioimmunotherapy for acute myeloid leukemia? Expert Opin Biol Ther. 2022;22(5):555–561. doi: 10.1080/14712598.2022.2060735.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Chen X, Feng S. Autologous hematopoietic stem cell transplantation in acute myelogenous leukemia. Biol Blood Marrow Transplant. 2019;25(9):e285–e292. doi: 10.1016/j.bbmt.2019.04.027.
   PubMed Web of Science ®Google Scholar
• Deshantri AK, Varela Moreira A, Ecker V, et al. Nanomedicines for the treatment of hematological malignancies. J Control Release. 2018;287:194–215. doi: 10.1016/j.jconrel.2018.08.034.
   PubMed Web of Science ®Google Scholar
• Zhong W, Zhang X, Zhao M, et al. Advancements in nanotechnology for the diagnosis and treatment of multiple myeloma. Biomater Sci. 2020;8(17):4692–4711. doi: 10.1039/D0BM00772B.
   PubMed Web of Science ®Google Scholar
• Mitchell MJ, Billingsley MM, Haley RM, et al. Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov. 2021;20(2):101–124. doi: 10.1038/s41573-020-0090-8.
   PubMed Web of Science ®Google Scholar
• Verma R, Chauhan A, Kumari S, et al. Green synthesis of ZnO NPs using timur (Zanthoxylum armatum DC.) plant extract for antimicrobial and dye degradation applications. Chem Pap. 2023;77(9):5587–5597. doi: 10.1007/s11696-023-02831-2.
   Web of Science ®Google Scholar
• Nath D, Banerjee P. Green nanotechnology - a new hope for medical biology. Environ Toxicol Pharmacol. 2013;36(3):997–1014. doi: 10.1016/j.etap.2013.09.002.
   PubMed Web of Science ®Google Scholar
• Sadjadi S, Mohammadi P, Heravi M. Bio-assisted synthesized Pd nanoparticles supported on ionic liquid decorated magnetic halloysite: an efficient catalyst for degradation of dyes. Sci Rep. 2020;10(1):6535. doi: 10.1038/s41598-020-63558-8.
   PubMed Web of Science ®Google Scholar
• Vinhas R, Mendes R, Fernandes AR, et al. Nanoparticles-emerging potential for managing leukemia and lymphoma. Front Bioeng Biotechnol. 2017;5:79. doi: 10.3389/fbioe.2017.00079.
   PubMed Web of Science ®Google Scholar
• Magdalena S, Dorota H. Biological activity of silver nanoparticles and their applications in anticancer therapy: silver nanoparticles. Rijeka: IntechOpen; 2018.
   Google Scholar
• Akshaya K, Arthi C, Pavithra AJ, et al. Bioconjugated gold nanoparticles as an efficient colorimetric sensor for cancer diagnostics. Photodiagnosis Photodyn Ther. 2020;30:101699. doi: 10.1016/j.pdpdt.2020.101699.
   PubMed Web of Science ®Google Scholar
• Namvar F, Rahman HS, Mohamad R, et al. Apoptosis induction in human leukemia cell lines by gold nanoparticles synthesized using the green biosynthetic approach. J Nanomater. 2015;2015:1–10. doi: 10.1155/2015/642621.
   Web of Science ®Google Scholar
• Bulbake U, Doppalapudi S, Kommineni N, et al. Liposomal formulations in clinical use: an updated review. Pharmaceutics. 2017;9(2):12. doi: 10.3390/pharmaceutics9020012.
   PubMed Web of Science ®Google Scholar
• Mayer LD, Tardi P, Louie AC. CPX-351: a nanoscale liposomal co-formulation of daunorubicin and cytarabine with unique biodistribution and tumor cell uptake properties. Int J Nanomedicine. 2019;14:3819–3830. doi: 10.2147/ijn.s139450.
   PubMed Web of Science ®Google Scholar
• Chen KTJ, Gilabert-Oriol R, Bally MB, et al. Recent treatment advances and the role of nanotechnology, combination products, and immunotherapy in changing the therapeutic landscape of acute myeloid leukemia. Pharm Res. 2019;36(9):125. doi: 10.1007/s11095-019-2654-z.
   PubMed Web of Science ®Google Scholar
• Mercy DJ, Harini K, Madhumitha S, et al. pH-responsive polymeric nanostructures for cancer theranostics. J Met Mater Miner. 2023;33(2):1–15. doi: 10.55713/jmmm.v33i2.1609.
   Web of Science ®Google Scholar
• Wang J, Hu S, Mao W, et al. Assemblies of peptide-cytotoxin conjugates for tumor-homing chemotherapy. Adv Funct Materials. 2019;29(32):1904925. doi: 10.1002/adfm.201904925.
   Web of Science ®Google Scholar
• Pallavi P, Harini K, Crowder S, et al. Rhodamine-conjugated anti-stokes gold nanoparticles with higher ROS quantum yield as theranostic probe to arrest cancer and MDR bacteria. Appl Biochem Biotechnol. 2023;195(11):6979–6993. doi: 10.1007/s12010-023-04475-0.
   PubMed Web of Science ®Google Scholar
• Ancona A, Dumontel B, Garino N, et al. Lipid-Coated zinc oxide nanoparticles as innovative ROS-generators for photodynamic therapy in cancer cells. Nanomaterials (Basel). 2018;8(3):143. doi: 10.3390/nano8030143.
   PubMedGoogle Scholar
• Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul. 2001;41(1):189–207. doi: 10.1016/s0065-2571(00)00013-3.
   PubMedGoogle Scholar
• D’Mello SR, Cruz CN, Chen ML, et al. The evolving landscape of drug products containing nanomaterials in the United States. Nat Nanotechnol. 2017;12(6):523–529. doi: 10.1038/nnano.2017.67.
   PubMed Web of Science ®Google Scholar
• Bertrand N, Wu J, Xu X, et al. Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. Adv Drug Deliv Rev. 2014;66:2–25. doi: 10.1016/j.addr.2013.11.009.
   PubMed Web of Science ®Google Scholar
• Huang X, Lin H, Huang F, et al. Targeting approaches of nanomedicines in acute myeloid leukemia. Dose Response. 2019;17(4):1559325819887048. doi: 10.1177/1559325819887048.
   Web of Science ®Google Scholar
• Mali P, Yang L, Esvelt KM, et al. RNA-guided human genome engineering via Cas9. Science. 2013;339(6121):823–826. doi: 10.1126/science.1232033.
   PubMed Web of Science ®Google Scholar
• Mihaila RG, Topircean D. The high-performance technology CRISPR/Cas9 improves knowledge and management of acute myeloid leukemia. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2021;165(3):249–257. doi: 10.5507/bp.2021.048.
   PubMed Web of Science ®Google Scholar
• Staahl BT, Benekareddy M, Coulon-Bainier C, et al. Efficient genome editing in the mouse brain by local delivery of engineered Cas9 ribonucleoprotein complexes. Nat Biotechnol. 2017;35(5):431–434. doi: 10.1038/nbt.3806.
   PubMed Web of Science ®Google Scholar
• Ho T-C, Kim HS, Chen Y, et al. Scaffold-mediated CRISPR-Cas9 delivery system for acute myeloid leukemia therapy. Sci Adv. 2021;7(21):eabg3217. doi: 10.1126/sciadv.abg3217.
   PubMed Web of Science ®Google Scholar
• Neldeborg S, Soerensen JF, Møller CT, et al. Dual intron-targeted CRISPR-Cas9-mediated disruption of the AML RUNX1-RUNX1T1 fusion gene effectively inhibits proliferation and decreases tumor volume in vitro and in vivo. Leukemia. 2023;37(9):1792–1801. doi: 10.1038/s41375-023-01950-9.
   PubMedGoogle Scholar
• Gurney M, Stikvoort A, Nolan E, et al. CD38 knockout natural killer cells expressing an affinity optimized CD38 chimeric antigen receptor successfully target acute myeloid leukemia with reduced effector cell fratricide. Haematologica. 2022;107(2):437–445. doi: 10.3324/haematol.2020.271908.
   PubMed Web of Science ®Google Scholar
• He BL, Yang N, Man CH, et al. Follistatin is a novel therapeutic target and biomarker in FLT3/ITD acute myeloid leukemia. EMBO Mol Med. 2020;12(4):e10895. doi: 10.15252/emmm.201910895.
   PubMed Web of Science ®Google Scholar
• Narimani M, Sharifi M, Jalili A. Knockout of BIRC5 gene by CRISPR/Cas9 induces apoptosis and inhibits cell proliferation in leukemic cell lines, HL60 and KG1. Blood Lymphat Cancer. 2019;9:53–61. doi: 10.2147/blctt.s230383.
   PubMed Web of Science ®Google Scholar
• McEwan B, Padalia Z, Porras A, et al. Allogeneic CRISPR/Cas9 gene-edited CAR-T cells targeting CD33 show potent preclinical activity against AML cells. Cancer Res. 2019;79(13_Supplement):1428–1428. doi: 10.1158/1538-7445.AM2019-1428.
   Web of Science ®Google Scholar
• Sharmiladevi P, Akhtar N, Haribabu V, et al. Excitation wavelength independent carbon-decorated ferrite nanodots for multimodal diagnosis and stimuli responsive therapy. ACS Appl Bio Mater. 2019;2(4):1634–1642. doi: 10.1021/acsabm.9b00039.
   PubMedGoogle Scholar
• Shurfa M, Girigoswami A, Devi RS, et al. Combinatorial effect of doxorubicin entrapped in Alginate-Chitosan hybrid polymer and cerium oxide nanocomposites on skin cancer management in mice. J Pharm Sci. 2023;112(11):2891–2900. doi: 10.1016/j.xphs.2023.08.014.
   PubMed Web of Science ®Google Scholar
• Poornima G, Harini K, Pallavi P, et al. RNA–a choice of potential drug delivery system. Int. J. Polym. 2022;72(10):778–792. doi: 10.1080/00914037.2022.2058946.
   Web of Science ®Google Scholar
• Zou M, Zhong Z, Wen C. Characterization and anti-acute myeloid leukemia and anti-acute T cell leukemia properties of zinc nanoparticles synthesized by a green approach for bioremediation applications. Arch Med Sci. 2021:140295. doi: 10.5114/aoms/140295.
   Google Scholar
• Adebayo IA, Usman AI, Shittu FB, et al. Boswellia dalzielii-mediated silver nanoparticles inhibited acute myeloid leukemia (AML) kasumi-1 cells by inducing cell cycle arrest. Bioinorg Chem Appl. 2020;2020:8898360–8898311. doi: 10.1155/2020/8898360.
   PubMed Web of Science ®Google Scholar
• Ahmeda A, Zangeneh M, Zangeneh A. Green formulation and chemical characterization of lens culinaris seed aqueous extract conjugated gold nanoparticles for the treatment of acute myeloid leukemia in comparison to mitoxantrone in a leukemic mouse model. Appl Organom Chem. 2020;34(3):e5369. doi: 10.1002/aoc.5369.
   Web of Science ®Google Scholar
• Banerjee P, Roy P, Nath D. Evaluation of chemopreventive potential and regulated toxicity of a phyto-fabricated silver nanoformulation using bark extract of saraca asoca in acute myeloid leukemia in vivo and in vitro. Curr Res Complement Altern Med. 2022;6:148. doi: 10.29011/2577-2201.100048.
   Google Scholar
• Hemmati S, Joshani Z, Zangeneh A, et al. Biosynthesis and chemical characterization of polydopamine-capped silver nanoparticles for the treatment of acute myeloid leukemia in comparison to doxorubicin in a leukemic mouse model. Appl Organom Chemis. 2020;34(2):e5277. doi: 10.1002/aoc.5277.
   Web of Science ®Google Scholar
• Ahmeda A, Zangeneh A, Zangeneh MM. Preparation, formulation, and chemical characterization of silver nanoparticles using Melissa officinalis leaf aqueous extract for the treatment of acute myeloid leukemia in vitro and in vivo conditions. Appl Organom Chem. 2020;34(2):e5378. doi: 10.1002/aoc.5378.
   Web of Science ®Google Scholar
• Kong F, Bai H, Ma M, et al. Fe3O4@Pt nanozymes combining with CXCR4 antagonists to synergistically treat acute myeloid leukemia. Nano Today. 2021;37:101106. doi: 10.1016/j.nantod.2021.101106.
   Web of Science ®Google Scholar
• Zangeneh M, Zangeneh A. Novel green synthesis of Hibiscus sabdariffa flower extract conjugated gold nanoparticles with excellent anti-acute myeloid leukemia effect in comparison to daunorubicin in a leukemic rodent model. Appl Organom Chem. 2019;34(1):e5271. doi: 10.1002/aoc.5271.
   Web of Science ®Google Scholar
• Shahriari M, Hemmati S, Zangeneh A, et al. Decoration of silver nanoparticles on multi-walled carbon nanotubes: investigation of its anti-acute leukemia property against acute myeloid leukemia and acute T cell leukemia. Appl Organom Chem. 2020;34(4):e5476. doi: 10.1002/aoc.5476.
   Web of Science ®Google Scholar
• Sun Y, Liu X, Wang L, et al. High-performance SOD mimetic enzyme Au@Ce for arresting cell cycle and proliferation of acute myeloid leukemia. Bioact Mater. 2022;10:117–130. doi: 10.1016/j.bioactmat.2021.08.012.
   PubMed Web of Science ®Google Scholar
• Dou J, Li L, Guo M, et al. Iron oxide nanoparticles combined with cytosine arabinoside show anti-leukemia stem cell effects on acute myeloid leukemia by regulating reactive oxygen species. Int J Nanomedicine. 2021;16:1231–1244. doi: 10.2147/ijn.s278885.
   PubMed Web of Science ®Google Scholar
• Wang X, Huang R, Wu W, et al. Amplifying STING activation by bioinspired nanomedicine for targeted chemo- and immunotherapy of acute myeloid leukemia. Acta Biomater. 2023;157:381–394. doi: 10.1016/j.actbio.2022.11.007.
   PubMed Web of Science ®Google Scholar
• Wang T, Zhang X, Jia M, et al. Hydrophilic realgar nanocrystals prolong the survival of refractory acute myeloid leukemia mice through inducing multi-lineage differentiation and apoptosis. Int J Nanomedicine. 2022;17:2191–2202. doi: 10.2147/ijn.s358469.
   PubMed Web of Science ®Google Scholar
• Bai H, Wang T, Kong F, et al. CXCR4 and CD44 dual-targeted prussian blue nanosystem with daunorubicin loaded for acute myeloid leukemia therapy. J Chem Eng. 2021;405:126891. doi: 10.1016/j.cej.2020.126891.
   Google Scholar
• Chen KTJ, Militao GGC, Anantha M, et al. Development and characterization of a novel flavopiridol formulation for treatment of acute myeloid leukemia. J Control Release. 2021;333:246–257. doi: 10.1016/j.jconrel.2021.03.042.
   PubMed Web of Science ®Google Scholar
• Chen M, Qiao Y, Cao J, et al. Biomimetic doxorubicin/ginsenoside co-loading nanosystem for chemoimmunotherapy of acute myeloid leukemia. J Nanobiotechnology. 2022;20(1):273. doi: 10.1186/s12951-022-01491-w.
   PubMed Web of Science ®Google Scholar
• Alhallak K, Sun J, Muz B, et al. Nanoparticle T cell engagers for the treatment of acute myeloid leukemia. Oncotarget. 2021;12(19):1878–1885. doi: 10.18632/oncotarget.28054.
   PubMedGoogle Scholar
• Darwish NHE, Sudha T, Godugu K, et al. Novel targeted nano-parthenolide molecule against NF-kB in acute myeloid leukemia. Molecules. 2019;24(11):2103. doi: 10.3390/molecules24112103.
   PubMed Web of Science ®Google Scholar
• Xie J, Zhao X, Zhang P, et al. Codelivery of BCL2 and MCL1 inhibitors enabled by phenylboronic acid-functionalized polypeptide nanovehicles for synergetic and potent therapy of acute myeloid leukemia. Adv Sci (Weinh). 2023;10(8):e2204866. doi: 10.1002/advs.202204866.
   PubMedGoogle Scholar
• Xia Y, An J, Li J, et al. Transferrin-guided intelligent nanovesicles augment the targetability and potency of clinical PLK1 inhibitor to acute myeloid leukemia. Bioact Mater. 2023;21:499–510. doi: 10.1016/j.bioactmat.2022.08.032.
   PubMed Web of Science ®Google Scholar
• Wang D, Li H, Chen W, et al. Efficient tumor-targeting delivery of siRNA via folate-receptor mediated biomimetic albumin nanoparticles enhanced by all-trans retinoic acid. Mater Sci Eng C Mater Biol Appl. 2021;119:111583. doi: 10.1016/j.msec.2020.111583.
   PubMed Web of Science ®Google Scholar
• Wang Y, Xie Y, Williams J, et al. Use of polymeric CXCR4 inhibitors as siRNA delivery vehicles for the treatment of acute myeloid leukemia. Cancer Gene Ther. 2020;27(1–2):45–55. doi: 10.1038/s41417-019-0095-9.
   PubMed Web of Science ®Google Scholar
• Vaikari VP, Park M, Keossayan L, et al. Anti-CD99 scFv-ELP nanoworms for the treatment of acute myeloid leukemia. Nanomedicine. 2020;29:102236. doi: 10.1016/j.nano.2020.102236.
   PubMed Web of Science ®Google Scholar
• Pallarès V, Núñez Y, Sánchez-García L, et al. Antineoplastic effect of a diphtheria toxin-based nanoparticle targeting acute myeloid leukemia cells overexpressing CXCR4. J Control Release. 2021;335:117–129. doi: 10.1016/j.jconrel.2021.05.014.
   PubMed Web of Science ®Google Scholar
• Nirachonkul W, Ogonoki S, Thumvijit T, et al. CD123-targeted nano-curcumin molecule enhances cytotoxic efficacy in leukemic stem cells. Nanomaterials (Basel). 2021;11(11):2974. doi: 10.3390/nano11112974.
   PubMedGoogle Scholar
• Kushwaha AC, Mohanbhai SJ, Sardoiwala MN, et al. Epigenetic regulation of Bmi1 by ubiquitination and proteasomal degradation inhibit bcl-2 in acute myeloid leukemia. ACS Appl Mater Interfaces. 2020;12(23):25633–25644. doi: 10.1021/acsami.0c06186.
   PubMed Web of Science ®Google Scholar
• Yu Y, Meng Y, Xu X, et al. A ferroptosis-inducing and leukemic cell-targeting drug nanocarrier formed by redox-responsive cysteine polymer for acute myeloid leukemia therapy. ACS Nano. 2023;17(4):3334–3345. doi: 10.1021/acsnano.2c06313.
   PubMed Web of Science ®Google Scholar
• Xu X, Wang J, Tong T, et al. A self-assembled leucine polymer sensitizes leukemic stem cells to chemotherapy by inhibiting autophagy in acute myeloid leukemia. Haematologica. 2022;107(10):2344–2355. doi: 10.3324/haematol.2021.280290.
   PubMed Web of Science ®Google Scholar
• Nguyen TM, Jambhrunkar M, Wong SS, et al. Targeting acute myeloid leukemia using sphingosine kinase 1 inhibitor-loaded liposomes. Mol Pharm. 2023;20(8):3937–3946. doi: 10.1021/acs.molpharmaceut.3c00078.
   PubMedGoogle Scholar
• Wang C, Zhang W, He Y, et al. Ferritin-based targeted delivery of arsenic to diverse leukaemia types confers strong anti-leukaemia therapeutic effects. Nat Nanotechnol. 2021;16(12):1413–1423. doi: 10.1038/s41565-021-00980-7.
   PubMed Web of Science ®Google Scholar
• Khokhlatchev AV, Sharma A, Deering TG, et al. Ceramide nanoliposomes augment the efficacy of venetoclax and cytarabine in models of acute myeloid leukemia. Faseb J. 2022;36(10):e22514. doi: 10.1096/fj.202200765R.
   PubMed Web of Science ®Google Scholar
• Hemmati S, Zamenian T, Delsooz N, et al. Preparation and synthesis a new chemotherapeutic drug of silver nanoparticle-chitosan composite; chemical characterization and analysis of their antioxidant, cytotoxicity, and anti-acute myeloid leukemia effects in comparison to daunorubicin in a leukemic mouse model. Appl Organom Chem. 2020;34(2):e5274. doi: 10.1002/aoc.5274.
   Web of Science ®Google Scholar
• Deng R, Shen N, Yang Y, et al. Targeting epigenetic pathway with gold nanoparticles for acute myeloid leukemia therapy. Biomater. 2018;167:80–90. doi: 10.1016/j.biomaterials.2018.03.013.
   PubMed Web of Science ®Google Scholar
• Shen N, Yan F, Pang J, et al. HDL-AuNPs-BMS nanoparticle conjugates as molecularly targeted therapy for leukemia. ACS Appl Mater Interfaces. 2018;10(17):14454–14462. doi: 10.1021/acsami.8b01696.
   PubMed Web of Science ®Google Scholar
• Zong H, Sen S, Zhang G, et al. In vivo targeting of leukemia stem cells by directing parthenolide-loaded nanoparticles to the bone marrow niche. Leukemia. 2016;30(7):1582–1586. doi: 10.1038/leu.2015.343.
   PubMed Web of Science ®Google Scholar
• Varshosaz J, Hassanzadeh F, Sadeghi Aliabadi H, et al. Synthesis and characterization of folate-targeted dextran/retinoic acid micelles for doxorubicin delivery in acute leukemia. Biomed Res Int. 2014;2014:525684–525614. doi: 10.1155/2014/525684.
   PubMed Web of Science ®Google Scholar
• Sun D, Zhou JK, Zhao L, et al. Novel curcumin liposome modified with hyaluronan targeting CD44 plays an anti-leukemic role in acute myeloid leukemia in vitro and in vivo. ACS Appl Mater Interfaces. 2017;9(20):16857–16868. doi: 10.1021/acsami.7b02863.
   PubMed Web of Science ®Google Scholar
• Guo J, Russell EG, Darcy R, et al. Antibody-targeted cyclodextrin-based nanoparticles for siRNA delivery in the treatment of acute myeloid leukemia: physicochemical characteristics, in vitro mechanistic studies, and ex vivo patient derived therapeutic efficacy. Mol Pharm. 2017;14(3):940–952. doi: 10.1021/acs.molpharmaceut.6b01150.
   PubMedGoogle Scholar
• Mandal T, Beck M, Kirsten N, et al. Targeting murine leukemic stem cells by antibody functionalized mesoporous silica nanoparticles. Sci Rep. 2018;8(1):989. doi: 10.1038/s41598-017-18932-4.
   PubMedGoogle Scholar
• Jiang X, Bugno J, Hu C, et al. Eradication of acute myeloid leukemia with FLT3 ligand-targeted miR-150 nanoparticles. Cancer Res. 2016;76(15):4470–4480. doi: 10.1158/0008-5472.can-15-2949.
   PubMed Web of Science ®Google Scholar
• Yang Z, Yu B, Zhu J, et al. A microfluidic method to synthesize transferrin-lipid nanoparticles loaded with siRNA LOR-1284 for therapy of acute myeloid leukemia. Nanoscale. 2014;6(16):9742–9751. doi: 10.1039/c4nr01510j.
   PubMed Web of Science ®Google Scholar
• Floc’h N, Ashton S, Taylor P, et al. Optimizing therapeutic effect of Aurora B inhibition in acute myeloid leukemia with AZD2811 nanoparticles. Mol Cancer Ther. 2017;16(6):1031–1040. doi: 10.1158/1535-7163.mct-16-0580.
   PubMed Web of Science ®Google Scholar
• Johnson DT, Zhou J, Kroll AV, et al. Acute myeloid leukemia cell membrane-coated nanoparticles for cancer vaccination immunotherapy. Leukemia. 2022;36(4):994–1005. doi: 10.1038/s41375-021-01432-w.
   PubMed Web of Science ®Google Scholar
• Li Q, Su R, Bao X, et al. Glycyrrhetinic acid nanoparticles combined with ferrotherapy for improved cancer immunotherapy. Acta Biomater. 2022;144:109–120. doi: 10.1016/j.actbio.2022.03.030.
   PubMed Web of Science ®Google Scholar
• Cao K, Du Y, Bao X, et al. Glutathione-bioimprinted nanoparticles targeting of N6-methyladenosine FTO demethylase as a strategy against leukemic stem cells. Small. 2022;18(13):e2106558. doi: 10.1002/smll.202106558.
   PubMed Web of Science ®Google Scholar
• Wang Q, Liu Y, Wang H, et al. Graphdiyne oxide nanosheets display selective anti-leukemia efficacy against DNMT3A-mutant AML cells. Nat Commun. 2022;13(1):5657. doi: 10.1038/s41467-022-33410-w.
   PubMed Web of Science ®Google Scholar
• Rajagopal P, Jayandharan GR, Krishnan UM. Evaluation of the anticancer activity of pH-sensitive polyketal nanoparticles for acute myeloid leukemia. Mol Pharm. 2021;18(5):2015–2031. doi: 10.1021/acs.molpharmaceut.0c01243.
   PubMedGoogle Scholar
• Du Y, Han M, Cao K, et al. Gold nanorods exhibit intrinsic therapeutic activity via controlling N6-methyladenosine-based epitranscriptomics in acute myeloid leukemia. ACS Nano. 2021;15(11):17689–17704. doi: 10.1021/acsnano.1c05547.
   PubMed Web of Science ®Google Scholar
• Foulkes R, Man E, Thind J, et al. The regulation of nanomaterials and nanomedicines for clinical application: current and future perspectives. Biomater Sci. 2020;8(17):4653–4664. doi: 10.1039/D0BM00558D.
   PubMed Web of Science ®Google Scholar
• Zhang X-Q, Xu X, Bertrand N, et al. Interactions of nanomaterials and biological systems: implications to personalized nanomedicine. Adv Drug Deliv Rev. 2012;64(13):1363–1384. doi: 10.1016/j.addr.2012.08.005.
   PubMed Web of Science ®Google Scholar
• Sun Q, Bai X, Sofias AM, et al. Cancer nanomedicine meets immunotherapy: opportunities and challenges. Acta Pharmacol Sin. 2020;41(7):954–958. doi: 10.1038/s41401-020-0448-9.
   PubMed Web of Science ®Google Scholar
• Thapa RK, Kim JO. Nanomedicine-based commercial formulations: current developments and future prospects. J Pharm Investig. 2023;53(1):19–33. doi: 10.1007/s40005-022-00607-6.
   PubMed Web of Science ®Google Scholar
• Metkar S, Girigoswami K. Diagnostic biosensors in medicine—a review. Biocatal Agric Biotechnol. 2019;17:271–283. doi: 10.1016/j.bcab.2018.11.029.
   Web of Science ®Google Scholar
• Abu-Salah KM, Alrokyan SA, Khan MN, et al. Nanomaterials as analytical tools for genosensors. Sensors (Basel). 2010;10(1):963–993. doi: 10.3390/s100100963.
   PubMed Web of Science ®Google Scholar
• Bordbar MM, Tashkhourian J, Hemmateenejad B. Structural elucidation and ultrasensitive analyses of volatile organic compounds by paper-based nano-optoelectronic noses. ACS Sens. 2019;4(5):1442–1451. doi: 10.1021/acssensors.9b00680.
   PubMed Web of Science ®Google Scholar
• Bordbar MM, Barzegar H, Tashkhourian J, et al. A non-invasive tool for early detection of acute leukemia in children using a paper-based optoelectronic nose based on an array of metallic nanoparticles. Anal Chim Acta. 2021;1141:28–35. doi: 10.1016/j.aca.2020.10.029.
   PubMed Web of Science ®Google Scholar
• Lubes G, Goodarzi M. GC-MS based metabolomics used for the identification of cancer volatile organic compounds as biomarkers. J Pharm Biomed Anal. 2018;147:313–322. doi: 10.1016/j.jpba.2017.07.013.
   PubMed Web of Science ®Google Scholar
• Tang H, Lu Y, Zhang L, et al. Determination of volatile organic compounds exhaled by cell lines derived from hematological malignancies. Biosci Rep. 2017;37(3):BSR20170106. doi: 10.1042/bsr20170106.
   Google Scholar
• Thevendran R, Foo KL, Hussin MH, et al. Reverse electrochemical sensing of FLT3-ITD mutations in acute myeloid leukemia using gold sputtered ZnO-Nanorod configured DNA biosensors. Biosensors (Basel). 2022;12(3):170. doi: 10.3390/bios12030170.
   PubMedGoogle Scholar
• Mayerhoefer ME, Archibald SJ, Messiou C, et al. MRI and PET/MRI in hematologic malignancies. J Magn Reson Imaging. 2020;51(5):1325–1335. doi: 10.1002/jmri.26848.
   PubMed Web of Science ®Google Scholar
• Dinani HS, Pourmadadi M, Yazdian F, et al. Fabrication of Au/Fe(3)O(4)/RGO based aptasensor for measurement of miRNA-128, a biomarker for acute lymphoblastic leukemia (ALL). Eng Life Sci. 2022;22(8):519–534. doi: 10.1002/elsc.202100170.
   PubMed Web of Science ®Google Scholar
• Ye M, Chen Y, Wang Y, et al. Subtype discrimination of acute myeloid leukemia based on plasma SERS technique. Spectrochim Acta A Mol Biomol Spectrosc. 2022;271:120865. doi: 10.1016/j.saa.2022.120865.
   PubMed Web of Science ®Google Scholar
• Đorđević S, Gonzalez MM, Conejos-Sánchez I, et al. Current hurdles to the translation of nanomedicines from bench to the clinic. Drug Deliv Transl Res. 2022;12(3):500–525. doi: 10.1007/s13346-021-01024-2.
   PubMed Web of Science ®Google Scholar